Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries ; volume:30 ; number:1 ; day:7 ; month:12 ; year:2023 ; pages:1-15 ; date:12.2023
Middle East current psychiatry ; 30, Heft 1 (7.12.2023), 1-15, 12.2023
- Creator
-
Ahmed, Nahida Nayaz
Albishi, Faisal
Khan, Suhail A.
Alsayegh, Ammar
Stip, Emmanuel
Makhoul, Samer
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s43045-023-00369-3
- URN
-
urn:nbn:de:101:1-2024020512230078354549
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ahmed, Nahida Nayaz
- Albishi, Faisal
- Khan, Suhail A.
- Alsayegh, Ammar
- Stip, Emmanuel
- Makhoul, Samer
- SpringerLink (Online service)
Other Objects (12)
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Personalized use of ketamine and esketamine for treatment-resistant depression
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
Virucidal gargling and virucidal nasal spray
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Personalized use of ketamine and esketamine for treatment-resistant depression
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
Virucidal gargling and virucidal nasal spray
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Personalized use of ketamine and esketamine for treatment-resistant depression
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant